Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Hodgkin Disease 1

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 34Whole-Body Irradiation 33Bortezomib 33ibrutinib 29Dexamethasone 27Tacrolimus 26Cyclosporine 25Busulfan 23Etoposide 22Melphalan 20Filgrastim 20zanubrutinib 18Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Flow Cytometry 10Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Indium 9Cyclosporins 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Neoadjuvant Therapy × Lymphoid × Clear all
NCT07259122 2025-12-02

ZBR in WM

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
43 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡